Document ID: chunk:federal_register_of_legislation:F2018L00869:clause:1_1:p8
Version: federal_register_of_legislation:F2018L00869
Segment Type: clause
Provision Reference: sch 1 cl 1 (pt 8/9)
Character Range: 33833–39102

means:
         (a)          alpha-adrenoceptor agonists;
         (b)          alprazolam;
         (c)          amantadine;
         (d)          amphetamines, including methamphetamine and 3,4-methylenedioxymethamphetamine (ecstasy);
         (e)          anabolic-androgenic steroids;
         (f)           angiotensin converting enzyme (ACE) inhibitors;
         (g)          antidepressants;
         (h)          antiepileptics, except valproate, lamotrigine and levetiracetam;
         (i)            armodafinil;
         (j)            atypical antipsychotics;
         (k)          baclofen;
         (l)            benzodiazepines;
         (m)        cannabis;
         (n)          centrally acting antihypertensives;
         (o)          chloroquine;
         (p)          clarithromycin;
         (q)          cocaine;
         (r)           corticosteroids, other than topical steroids;
         (s)           depot medroxyprogesterone acetate;
         (t)            dextromethorphan;
         (u)          digoxin;
         (v)          disulfiram;
         (w)        dopaminergic anti-Parkinsonian drugs;
         (x)          ephedrine;
         (y)          eszopiclone;
         (z)          fenfluramine;
         (aa)       fluoroquinolones;
         (bb)      fluphenazine;
         (cc)       fluspirilene;
         (dd)      gonadotropin releasing agents;
         (ee)       hallucinogens;
         (ff)        hydralazine;
         (gg)      hydroxychloroquine;
         (hh)      ifosfamide;
         (ii)         interferons;
         (jj)         interleukin-2;
         (kk)      intravenous 5-flurouracil;
         (ll)         iproniazid;
         (mm) isocarboxazid;
         (nn)      isoetharine;
         (oo)      isoniazid;
         (pp)      levothyroxine;
         (qq)      mefloquine;
         (rr)        methylphenidate;
         (ss)        modafinil;
         (tt)         mycophenolate mofetil;
         (uu)      opioids;
         (vv)      oral contraceptive agents;
         (ww)  phencyclidine;
         (xx)      phentermine;
         (yy)      phenylephrine;
         (zz)       phenylpropanolamine;
         (aaa)   pseudoephedrine;
         (bbb)  quinagolide;
         (ccc)   ramelteon;
         (ddd)  reserpine;
         (eee)   rimonabant;
         (fff)      thiazide;
         (ggg)  thyroxine;
         (hhh)  varenicline;
         (iii)       zaleplon; or
         (jjj)       zolpidem.
                                  Specified List 1 of clinically significant disorders of mental health means one of the following conditions, which is of sufficient severity to warrant ongoing management:
         (a)          acute stress disorder;
         (b)          agoraphobia;
         (c)          anxiety disorder;
         (d)          obsessive-compulsive disorder;
         (e)          panic disorder;
         (f)           posttraumatic stress disorder;
         (g)          social anxiety disorder; or
         (h)          specific phobia.
         Note 1:               "Management" of the condition may involve regular visits (for example, at least monthly) to a psychiatrist, counsellor or general practitioner.
         Note 2:               To "warrant ongoing management" does not require that any actual management was received or given for the condition.
                               Specified List 2 of clinically significant disorders of mental health means one of the following conditions, which is of sufficient severity to warrant ongoing management:
         (a)          acute stress disorder;
         (b)          agoraphobia;
         (c)          alcohol use disorder;
         (d)          anxiety disorder;
         (e)          attention-deficit/hyperactivity disorder;
         (f)           depressive disorder due to another medical condition;
         (g)          disruptive impulse-control and conduct disorder;
         (h)          eating disorder;
         (i)            obsessive-compulsive disorder;
         (j)            panic disorder;
         (k)          personality disorder;
         (l)            posttraumatic stress disorder;
         (m)        premenstrual dysphoric disorder;
         (n)          social anxiety disorder;
         (o)          specific phobia;
         (p)          substance use disorder; or
         (q)          substance/medication-induced depressive disorder.
         Note 1:               "Management" of the condition may involve regular visits (for example, at least monthly) to a psychiatrist, counsellor or general practitioner.
         Note 2:  To "warrant ongoing management" does not require that any actual management was received or given for the condition.
         Note 3: Depressive disorder due to another medical condition, premenstrual dysphoric disorder and substance/medication-induced depressive disorder are types of depressive disorders.
                               substance/medication-induced bipolar and related disorder means a disorder of mental health that meets the following diagnostic criteria (derived from DSM-5):
         1. A prominent and persistent disturbance in mood that predominates in the clinical picture and is characterised by elevated, expansive, or irritable mood,